Weekly Policy Update: House Bill 1260 Prescription Drug Transparency, plus the Advamed Fly-In in Washington, D.C.
By: Colorado BioScience Association Date: 03/02/2018
Urge a NO Vote on HB 1260, Prescription Drug Price Transparency
This week CBSA opposed a new bill introduced by the Colorado House that could adversely impact the Colorado bioscience industry, House Bill 1260, Prescription Drug Price Transparency. We need your help to contact your legislator URGING a NO VOTE. The legislation that was originally scheduled to be heard this week in the House Health, Insurance and Environment Committee but will now be heard next week. We need your help, please contact your legislator today!
At CBSA we are dedicated to patients, ensuring people live longer, healthier lives. That’s why we support true transparency. True transparency means:
- Working together to provide patients access to affordable medicines
- Addressing the health care system as a whole.
- Considering every player in the health care system to make meaningful changes for patients and their families.
To learn more, visit the Colorado BioScience Association’s True Transparency advocacy campaign. And be sure follow CBSA on social media to view, like, and share our true transparency posts on Facebook, Twitter and LinkedIn.
This month CBSA vice president Jennifer Jones and CBSA Board Member, policy committee co-chair, Dan Wittenberg, were in Washington, D.C. as part of the AdvaMed SMTA Fly In. This event brings medical technology representatives from across the country together for two days of legislative briefings and advocacy. There is a lot happening in the field, and we want to make sure Washington continues to promote the success of our Colorado companies. In addition to advocating for CBSA Federal Policy priorities we discussed with the delegation ways to ensure Patient Access to Critical Breakthrough Products, the value of medical technology, CO’s medtech economic impact, and thanked our elected officials for their leadership and hard work for the recent suspension of the medical device excise tax and discussed what we’d like to work towards in the future in terms of a permanent repeal.
To read the full CBSA policy update in the February Monthly newsletter click here.